Univariate and multivariate analysis for OS and TTFT
| Variable . | Univariate analysis . | Multivariate analysis, n = 228 . | ||||
|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | After bootstrapping . | ||
| HR (95% CI) . | P . | |||||
| OS | ||||||
| CLL-IPI | ||||||
| Low | 1 | 1 | 1 | |||
| Intermediate | 2.593 (1.121-6.001) | .026 | 2.074 (0.853-5.237) | .108 | 2.074 (0.822-5.049) | .122 |
| High | 4.828 (2.152-10.834) | <.001 | 5.716 (2.434-13.423) | <.001 | 5.716 (2.516-12.989) | <.001 |
| Very high | 13.628 (4.742-39.166) | <.001 | 4.875 (1.399-16.984) | .013 | 4.875 (1.161-20.477) | .031 |
| CIRS ≤6/>6 | 3.843 (2.433-6.071) | <.001 | 2.899 (1.521-5.523) | .001 | 2.899 (1.352-6.217) | .006 |
| CK, yes/no | 3.176 (1.882-5.359) | <.001 | 3.572 (1.572-8.116) | .002 | 3.572 (1.341-9.515) | .011 |
| TTFT | ||||||
| CLL-IPI | ||||||
| Low | 1 | 1 | 1 | |||
| Intermediate | 6.640 (2.993-14.729) | <.001 | 6.214 (2.788-13.853) | <.001 | 6.214 (2.171-17.790) | .001 |
| High | 20.831 (9.588-45.260) | <.001 | 22.308 (10.214-48.720) | <.001 | 22.308 (7.718-64.480) | <.001 |
| Very high | 25.637 (9.748-67.425) | <.001 | 15.811 (5.611-44.555) | <.001 | 15.811 (4.425-56.502) | <.001 |
| CIRS ≤6/>6 | 1.151 (0.794-1.669) | .407 | — | — | — | — |
| CK, yes/no | 2.521 (1.606-3.958) | <.001 | 2.157 (1.185-3.926) | .012 | 2.157 (1.177-3.952) | .013 |
| Variable . | Univariate analysis . | Multivariate analysis, n = 228 . | ||||
|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | After bootstrapping . | ||
| HR (95% CI) . | P . | |||||
| OS | ||||||
| CLL-IPI | ||||||
| Low | 1 | 1 | 1 | |||
| Intermediate | 2.593 (1.121-6.001) | .026 | 2.074 (0.853-5.237) | .108 | 2.074 (0.822-5.049) | .122 |
| High | 4.828 (2.152-10.834) | <.001 | 5.716 (2.434-13.423) | <.001 | 5.716 (2.516-12.989) | <.001 |
| Very high | 13.628 (4.742-39.166) | <.001 | 4.875 (1.399-16.984) | .013 | 4.875 (1.161-20.477) | .031 |
| CIRS ≤6/>6 | 3.843 (2.433-6.071) | <.001 | 2.899 (1.521-5.523) | .001 | 2.899 (1.352-6.217) | .006 |
| CK, yes/no | 3.176 (1.882-5.359) | <.001 | 3.572 (1.572-8.116) | .002 | 3.572 (1.341-9.515) | .011 |
| TTFT | ||||||
| CLL-IPI | ||||||
| Low | 1 | 1 | 1 | |||
| Intermediate | 6.640 (2.993-14.729) | <.001 | 6.214 (2.788-13.853) | <.001 | 6.214 (2.171-17.790) | .001 |
| High | 20.831 (9.588-45.260) | <.001 | 22.308 (10.214-48.720) | <.001 | 22.308 (7.718-64.480) | <.001 |
| Very high | 25.637 (9.748-67.425) | <.001 | 15.811 (5.611-44.555) | <.001 | 15.811 (4.425-56.502) | <.001 |
| CIRS ≤6/>6 | 1.151 (0.794-1.669) | .407 | — | — | — | — |
| CK, yes/no | 2.521 (1.606-3.958) | <.001 | 2.157 (1.185-3.926) | .012 | 2.157 (1.177-3.952) | .013 |
TTFT was calculated as the interval between diagnosis and the start of first-line treatment. OS was calculated from the date of diagnosis until death due to any cause or until the last patient follow-up. Proportional hazards regression analysis was used to identify the significant independent prognostic variables on TTFT. The stability of the Cox model was internally validated using bootstrapping procedures.4 Statistical analysis was performed using Stata 14.0 (Stata Corp, College Station, TX).
—, not applicable; CI, confidence interval; HR, hazard ratio.